Design And Development Of Mucoadhesive Microspheres Of AntiVertigo Agent For Nasal Delivery

Abstract

Mucoadhesive drug delivery systems are made to keep a formulation in close contact with the mucosal surface, this allows the drug to remain at the site of absorption for an extended period of time. The goal of this study is to create and assess mucoadhesive microspheres for the nasal delivery of Betahistine, as an antivertigo medication. The study's objectives were to reduce hepatic first-pass metabolism, increase therapeutic efficacy, and extend the duration of drug residency in the nasal cavity. Using chitosan as the mucoadhesive polymer and the emulsification cross-linking process, Betahistine-loaded mucoadhesive microspheres were created. Particle size distribution, percentage yield, drug entrapment efficiency, swelling index, in-vitro drug release, and in-vitro mucoadhesive strength were among the physicochemical and performance characteristics that were assessed for the produced microspheres. In order to evaluate formulation integrity over time, stability experiments were also carried out. Surface morphology and structural compatibility were examined using FTIR and SEM. The produced microspheres showed particle sizes between 10 and 50 µm, suggesting that they were suitable for nasal delivery and had acceptable handling qualities. A regulated release profile lasting up to six hours was shown in in vitro drug release experiments conducted in phosphate buffer with a pH of 6.8. The release kinetics indicates that all formulations shows zero order release kinetics that is controlled release pattern. According to the results, the produced mucoadhesive microsphere system offers a great deal of promise as a nasal delivery method for Betahistine, providing better therapeutic treatment of